Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could spot dangerous placenta condition earlier

NCT ID NCT02302573

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special ultrasound using contrast dye can better diagnose placenta accreta, a condition where the placenta grows too deeply into the womb and can cause severe bleeding after birth. Researchers studied 80 pregnant women at high risk for this condition. The goal was to see if this imaging method is more accurate than current standard tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Start date

May 2009

Finished

Aug 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant patient having any of the following two conditions: * Scar uterus (previous cesarean) with placenta previa partly or wholly on the uterine scar * Placenta praevia and patient aged over 35 years * Term \> 34 weeks of amenorrhea * More than 18 years old * Inform consent form signed * affiliated to medical insurrance Exclusion Criteria: * Inability to understand information * Contraindications to the contrast medium Sonovue: * Hypersensitivity to hexafluorinated sulphur or any other components of Sonovue * Recent acute coronary syndrome (within 6 months before the intervention) * Unstable ischemic heart disease (myocardial infarction being formed or evolving, typical angina of rest in the previous month) * Significant worsening of cardiac symptoms between the pre anaesthesia consultation and intervention * Recent intervention (less than 6 months) on coronary arteries or other factor suggesting clinical instability (changes in ECG, changes in clinical or biological parameters) * Acute heart failure or heart failure stage III or IV * Severe arrhythmias * Right-left shunt * Acute endocarditis * Valve prothesis * Severe pulmonary hypertension (pulmonary artery pressure \> 90mmHg) * Systemic hypertension uncontrolled * Respiratory distress syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Placenta accreta are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

placenta accreta

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Placenta accreta

Contacts and locations

Locations

  • CHU La Millétrie

    Poitiers, 86000, France

  • University Hospital of Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.